...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Progression of Coronary Artery Calcium and Occurrence of Myocardial Infarction in Patients With and Without Diabetes Mellitus
【24h】

Progression of Coronary Artery Calcium and Occurrence of Myocardial Infarction in Patients With and Without Diabetes Mellitus

机译:糖尿病患者与非糖尿病患者冠状动脉钙化的进展及心肌梗死的发生

获取原文
           

摘要

Progression of coronary artery calcium, a marker of atherosclerosis, can be slowed with statins, and continued progression of calcium is associated with an increased risk of myocardial infarction. However, it is not known whether statins are effective in slowing calcium progression in diabetes mellitus. In a retrospective study, we examined 1153 nondiabetic and 157 diabetic subjects who underwent sequential electron beam tomography scans at a minimum 1-year interval to assess progression of coronary calcium. A yearly score increase >15% was considered evidence of true progression. The use of statins and occurrence of myocardial infarction were recorded. There was no difference in baseline calcium score between diabetic and nondiabetic patients. Diabetic patients with no coronary calcium on the baseline scans developed it more often than nondiabetic subjects (42% versus 25%; P =0.046) during follow-up. Calcium progression was 33% greater in diabetic patients than nondiabetic subjects ( P <0.001) if no statin therapy was provided and 17.7% greater when statins were used ( P <0.001). Among the 49 subjects who experienced a myocardial infarction, the calcium score increased on average 20% more in diabetic than nondiabetic patients ( P <0.001). In logistic models, diabetes mellitus and systemic hypertension were the best predictors of calcium progression (odds ratio, 3.1 and 1.9, respectively), whereas baseline calcium score percentile and statin therapy were the best predictors of infarction. These findings support the notion that diabetes mellitus causes accelerated atherosclerosis, even in the presence of statin therapy, and provide evidence that coronary calcium monitoring is an effective method to assess treatment efficacy.
机译:他汀类药物可以减慢冠状动脉钙(动脉粥样硬化的标志物)的进程,而钙的持续进程与心肌梗塞的风险增加有关。然而,他汀类药物是否能有效减缓糖尿病的钙进程尚不明确。在一项回顾性研究中,我们检查了1153位非糖尿病患者和157位糖尿病患者,他们接受了至少1年间隔的连续电子束断层扫描,以评估冠状动脉钙的进展。年度分数增加> 15 %被认为是真实进展的证据。记录他汀类药物的使用和心肌梗塞的发生。糖尿病患者和非糖尿病患者的基线钙评分没有差异。在随访期间,基线扫描无冠状动脉钙化的糖尿病患者比非糖尿病患者更易发生冠状动脉钙化(42%,而非25%; P = 0.046)。如果未提供他汀类药物治疗,则糖尿病患者的钙进展比非糖尿病受试者高33%(P <0.001),而使用他汀类药物时,钙进展高17.7%(P <0.001)。在经历过心肌梗塞的49位受试者中,糖尿病患者的钙得分平均比非糖尿病患者高出20%(P <0.001)。在逻辑模型中,糖尿病和全身性高血压是钙进展的最佳预测因子(几率分别为3.1和1.9),而基线钙分数百分位数和他汀类药物治疗则是梗死的最佳预测因子。这些发现支持了即使在他汀类药物治疗的情况下糖尿病也会导致动脉粥样硬化加速的观点,并提供证据表明冠脉钙蛋白监测是评估治疗效果的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号